Article
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 7 Aug 2023
Morgan Robert D, Clamp Andrew R, Barnes Bethany M, Timms Kirsten, Schlecht Helene, Yarram-Smith Laura, Wallis Yvonne, Valganon-Petrizan Mikel, MacMahon Suzanne, White Rhian, Morgan Sian, McKenna Sarah, Hudson Emma, Tookman Laura, George Angela, Manchanda Ranjit, Sundar Sudha S, Nicum Shibani, Brenton James D, Kristeleit Rebecca S, Banerjee Susana, McNeish Iain A, Ledermann Jonathan A, Taylor Stephen S, Evans D Gareth R, Jayson Gordon C
Abstract excerpt
OBJECTIVE: Olaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the first year of routine homologous recombination deficiency testing in the National Health Service (NHS) in England, Wales, and Northern Ireland between April 2021 and April 2022. METHODS: The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.